{"nctId":"NCT01994720","briefTitle":"[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]","startDateStruct":{"date":"2014-01-07","type":"ACTUAL"},"conditions":["Acute Ischaemic Stroke","Transient Ischaemic Attack"],"count":13307,"armGroups":[{"label":"ticagrelor","type":"EXPERIMENTAL","interventionNames":["Drug: ticagrelor"]},{"label":"Acetylsalicylic acid (ASA)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Acetylsalicylic acid (ASA)"]}],"interventions":[{"name":"ticagrelor","otherNames":[]},{"name":"Acetylsalicylic acid (ASA)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Men or women equal or elder 40 years of age\n* Either acute ischaemic stroke or high-risk TIA as defined here and randomisation occurring within 24 hours after onset of symptoms\n\nKey Exclusion Criteria:\n\n* Planned use of antithrombotic therapy in addition to study medication including antiplatelets (eg, open label ASA, GPIIb/IIIa inhibitors, clopidogrel, ticlopidine, prasugrel, dipyridamole, ozagrel, cilostazol) and anticoagulants (eg, warfarin, oral thrombin and factor Xa inhibitors, bivalirudin, hirudin, argatroban, unfractionated and low molecular weight heparins). - Any history of atrial fibrillation, ventricular aneurysm or suspicion of cardioembolic pathology for TIA or stroke. - Planned carotid, cerebrovascular, or coronary revascularisation that requires halting study medication within 7 days of randomisation. - Receipt of any intravenous or intra-arterial thrombolysis or mechanical thrombectomy within 24 hours prior to randomisation - History of previous symptomatic non-traumatic intracerebral bleed at any time (asymptomatic microbleeds do not qualify), gastrointestinal (GI) bleed within the past 6 months, or major surgery within 30 days.","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","maximumAge":"130 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Composite of Stroke/MI/Death","description":"Participants with stroke, MI or death. If no event, censoring occures at the minimum of (last date of event assessment, end of treatment date, day 97).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"442","spread":null},{"groupId":"OG001","value":"497","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Ischaemic Stroke","description":"Participants with ischaemic stroke. If no event, censoring occures at the minimum of (last date of event assessment, date of death, end of treatment date, day 97).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"385","spread":null},{"groupId":"OG001","value":"441","spread":null}]}]}]},{"type":"SECONDARY","title":"Net Clinical Outcome","description":"Participants with stroke, MI, death or life-threatening bleeding. If no event, censoring occures at the minimum of (last date of event assessment, end of treatment date, day 97).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"457","spread":null},{"groupId":"OG001","value":"508","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Composite of Ischaemic Stroke, MI and CV Death","description":"Participants with ischaemic stroke, MI or CV death. If no event, censoring at the minimum of (last date of event assessment, date of death from non-CV causes, end of treatment date, day 97).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"423","spread":null},{"groupId":"OG001","value":"475","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With All-Cause Death","description":"Participants with all-cause death. If no event, censoring at the minimum of (last date of event assessment, end of treatment date, day 97).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null},{"groupId":"OG001","value":"58","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With CV Death","description":"Participants with CV death. If no event, censoring at the minimum of (last date of event assessment, date of death from non-CV causes, end of treatment date, day 97).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With MI","description":"Participants with MI. If no event, censoring at the minimum of (last date of event assessment, date of death, end of treatment date, day 97)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants by Severity of Stroke and Overall Disability","description":"Analysis of severity of stroke and overall disability of patients, using the modified Rankin Score, mRS.\n\nModified Rankin Score:\n\n0 - No symptoms.\n\n1. \\- No significant disability. Able to carry out all usual activities, despite some symptoms.\n2. \\- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.\n3. \\- Moderate disability. Requires some help, but able to walk unassisted.\n4. \\- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.\n5. \\- Severe disability. Requires constant nursing care and attention, bedridden, incontinent.\n6. \\- Dead.\n\nDisability defined as mRS \\> 1.\n\nOdds ratio and p-value are calculated for ticagrelor versus ASA from a logistic regression model with treatment group, history of stroke and NIHSS (National Institutes of Health Stroke Scale) at baseline as explanatory variables.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1107","spread":null},{"groupId":"OG001","value":"1194","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Stroke","description":"Participants with stroke. If no event, censoring at the minimum of (last date of event assessment, date of death, end of treatment date, day 97)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"390","spread":null},{"groupId":"OG001","value":"450","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Fatal Stroke","description":"Participants with fatal stroke. If no event, censoring at the minimum of (last date of event assessment, date of death from non-CV causes, end of treatment date, day 97).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Disabling Stroke","description":"Participants with disabling stroke. If no event, censoring at the minimum of (last date of event assessment, date of death, end of treatment date, day 97).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"277","spread":null},{"groupId":"OG001","value":"307","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in NIHSS","description":"Change from baseline to end of treatment visit in NIHSS (National Institutes of Health Stroke Scale):\n\n0 No stroke symptoms 1-4 Minor stroke 5-15 Moderate stroke 16-20 Moderate to severe stroke 21-42 Severe stroke.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"132","spread":null},{"groupId":"OG001","value":"127","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"403","spread":null},{"groupId":"OG001","value":"438","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"779","spread":null},{"groupId":"OG001","value":"810","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1088","spread":null},{"groupId":"OG001","value":"1073","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1099","spread":null},{"groupId":"OG001","value":"1131","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"681","spread":null},{"groupId":"OG001","value":"683","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"79","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"474","spread":null},{"groupId":"OG001","value":"450","spread":null}]}]}]},{"type":"SECONDARY","title":"EQ-5D at Visit 1 (Enrolment)","description":"EQ-5D (EuroQol five dimensions questionnaire) index score using the UK tariff.\n\nEQ-5D is a self assessment of 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. For each dimension responders are asked to state their status on a three level ordinal scale; whether they experience no problems (Level 1), some problems (Level 2) or severe problems (Level 3). Health states defined by the 5 dimensions can be converted into a weighted health state index (health state utility) by applying scores from the EQ-5D value sets elicited from general population samples.\n\nThe higher the index score the better the health state. In this study index scores ran from -0.59 to 1.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.70","spread":"0.297"},{"groupId":"OG001","value":"0.70","spread":"0.298"}]}]}]},{"type":"SECONDARY","title":"EQ-5D at Visit 2 (Day 7+-2d)","description":"EQ-5D (EuroQol five dimensions questionnaire) index score using the UK tariff.\n\nEQ-5D is a self assessment of 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. For each dimension responders are asked to state their status on a three level ordinal scale; whether they experience no problems (Level 1), some problems (Level 2) or severe problems (Level 3). Health states defined by the 5 dimensions can be converted into a weighted health state index (health state utility) by applying scores from the EQ-5D value sets elicited from general population samples.\n\nThe higher the index score the better the health state. In this study index scores ran from -0.59 to 1.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.80","spread":"0.244"},{"groupId":"OG001","value":"0.79","spread":"0.262"}]}]}]},{"type":"SECONDARY","title":"EQ-5D (EuroQol Five Dimensions Questionnaire) at End of Treatment Visit","description":"EQ-5D index score using the UK tariff.\n\nEQ-5D is a self assessment of 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. For each dimension responders are asked to state their status on a three level ordinal scale; whether they experience no problems (Level 1), some problems (Level 2) or severe problems (Level 3). Health states defined by the 5 dimensions can be converted into a weighted health state index (health state utility) by applying scores from the EQ-5D value sets elicited from general population samples.\n\nThe higher the index score the better the health state. In this study index scores ran from -0.59 to 1.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.85","spread":"0.203"},{"groupId":"OG001","value":"0.84","spread":"0.208"}]}]}]},{"type":"SECONDARY","title":"EQ-5D (EuroQol Five Dimensions Questionnaire) at Premature Treatment Discontinuation Visit","description":"EQ-5D index score using the UK tariff.\n\nEQ-5D is a self assessment of 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. For each dimension responders are asked to state their status on a three level ordinal scale; whether they experience no problems (Level 1), some problems (Level 2) or severe problems (Level 3). Health states defined by the 5 dimensions can be converted into a weighted health state index (health state utility) by applying scores from the EQ-5D value sets elicited from general population samples.\n\nThe higher the index score the better the health state. In this study index scores ran from -0.59 to 1.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.72","spread":"0.330"},{"groupId":"OG001","value":"0.68","spread":"0.364"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With PLATO Major Bleeding Event","description":"Participants with PLATO Major bleeding. If no event, censoring occures at the minimum of (last date of event assessment, date of death, end of treatment date, day 97).\n\nPLATO Major bleeding is defined as a bleed that is any one of:\n\n* Fatal\n* Intracranial (excluding asymptomatic haemorrhagic transformations of ischemic brain infarctions and excluding micro-hemorrhages \\<10 mm evident only on gradient-echo MRI)\n* Intrapericardial bleed with cardiac tamponade\n* Hypovolaemic shock or severe hypotension due to bleeding and requiring pressors or surgery\n* Significantly disabling (eg. intraocular with permanent vision loss)\n* Clinically overt or apparent bleeding associated with a decrease in Hb of more than 30 g/L (1.9 mmol/L; 0.465 mmol/L)\n* Transfusion of 2 or more units (whole blood or packed red blood cells \\[PRBCs\\]) for bleeding.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"38","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Premature Discontinuation of Study Drug Due to Any Bleeding Adverse Event","description":"Participants discontinuation of study drug due to any bleeding adverse event. If no event, censoring occures at the minimum of (last date of event assessment, date of death, end of treatment date, day 97).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82","spread":null},{"groupId":"OG001","value":"37","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":533,"n":6581},"commonTop":["Dyspnoea"]}}}